China: Healthcare

On May 7, 2026, China’s National Medical Products Administration (NMPA), in conjunction with six other government agencies, issued the Management Measures for Medical Representatives (Management Measures, 医药代表管理办法), which will take effect on August 1, 2026.

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.

On August 28, 2024, the National Medical Products Administration (NMPA) released the Medical Device Administration Law (Draft for Comment)...

The fourth amendment to the Patent Law of the People's Republic of China (hereinafter, the "Patent Law") came into effect on June 1, 2021. In July of the same year, the Measures for the Implementation...

ドイツの医療機器大手シーメンス・ヘルスケアは、第8回中国国際輸入博覧会（CIIE）において、重篤疾患の診断・治療分野に関する先端技術製品

On March 28, 2023, the Hainan Provincial People's Government officially issued the "Regulations on the Administration of Imported Drugs and Medical Devices Urgently Needed in Clinical Needs...

On April 4, 2023, the Ministry of Science and Technology released the "Measures for Science and Technology Ethics Review (Trial) (Draft for Comments)" ("Draft for Comments")...

2023年5月9日，国家卫健委科教司发布《体细胞临床研究工作指引（征求意见稿）》（" 《征求意见稿》"），并面向社会公开征求意见。体细胞治疗